TAPE/#

Speaker

Comments

TAPE 24, A

005

Chair Morrisette

Calls the meeting to order at 3:07 p.m.  Opens public hearing on SB 756 for Senator Alan Bates to testify.

SB 756 – PUBLIC HEARING

010

Rick Berkobien

Committee Administrator.  Explains the bill.

017

Sen. Alan Bates

Senate District #3. Testifies in support of SB 756.

035

Sen. C. Starr

Asks if the intent of the bill is to avoid pregnancy.

040

Sen. Bates

Clarifies the intent of the bill.

045

Chair Morrisette

Recesses public hearing on SB 756 and opens a public hearing on SB 180.

SB 180 – PUBLIC HEARING

048

Rick Berkobien

Committee Administrator.  Introduces -1 amendments (EXHIBIT A).

050

John Horton

Associate Deputy Director, State and Local Affairs, White House Office of National Drug Control Policy.  Submits and presents written testimony with a neutral position on SB 180 (EXHIBIT B).

095

Chair Morrisette

Opens into a subcommittee.

100

Horton

Continues to discuss the background of drug abuse.

150

Horton

Summarizes and concludes.

190

Sen. Kruse

Asks if SB 180 is similar to Nevada’s and Idaho’s program.

192

Horton

Defers to individuals representing those states.

195

Sen. Kruse

Asks how much federal money Oregon will receive to manage the Methamphetamine problem.

198

Horton

Comments on funds that have been requested, but notes that it is a cut from previous years.

203

Sen. Kruse

Comments on locally funded law enforcement programs that attempt to cut methamphetamine users, and suggests that they may be the most effective programs.

210

Horton

Comments on the program Sen. Kruse discussed.

218

Sen. Monnes Anderson

Asks how to deal with issue of people who abuse prescription drugs.

230

Horton

Comments on how to treat people who abuse prescription drugs.

290

Gary Schnabel

Executive Director, Oregon State Board of Pharmacy.  Submits and presents written testimony in support of SB 180 (EXHIBIT C), graph of states with prescription monitoring programs currently operating (EXHIBIT D), informational packet (EXHIBIT E), and unofficial amendments (EXHIBIT F).

340

Schnabel

Continues to discuss support of SB 180.

390

Schnabel

Continues to discuss support of SB 180.

430

Schnabel

Summarizes and concludes.

TAPE 25, A

025

Keith MacDonald

Executive Secretary, Nevada Board of Pharmacy. Submits and presents report on the state of Nevada’s prescription controlled substance abuse prevention task force in support of SB 180 (EXHIBIT G).

075

MacDonald

Continues discussing testimony about Nevada’s Prescription substance abuse prevention task force.

125

MacDonald

Continues discussing testimony about Nevada’s Prescription substance abuse prevention task force.

175

MacDonald

Discusses the people who have benefited from their program.

200

Richard Mick Markuson

Director, Idaho Board of Pharmacy.  Reviews slide presentation about Idaho’s drug tracking program.

230

Sen. Monnes Anderson

Asks Markuson to classify their schedule classification when referring to drugs.

238

Markuson

Explains schedule I drugs and that they have no medical purpose.

270

Morrisette

Asks to confirm that marijuana is under Schedule I.

272

Markuson

Affirms.

275

Sen. Morrisette

Informs witness that Oregon has a medical Marijuana law.

285

Sen. Monnes Anderson

Asks Markuson to explain Schedule II drug classification.

286

Markuson

Explains Schedule II.

290

Sen. Morrisette

Asks for examples for each Schedule.

292

Markuson

Provides examples.  Continues to review slide presentation of Idaho’s drug tracking program.

345

Sen. Monnes Anderson

Asks if the information could be broken down by age or sex.

350

Markuson

Answers that they do have the data. Continues to review slide presentation of Idaho’s drug tracking program.

390

Markuson

Explains why the program works so effectively.

TAPE 24, B

003

Sen. Metsger

Refers to page 1, section 2, lines 25 and 26 of the bill.  Asks Schnabel to clarify the authority given in the bill.

008

Schnabel

Affirms authority given and elaborates.

020

Sen. Metsger

Comments on concern of section 3 of bill.  Refers to page 2, section 3, lines 18 through 23 and compares to lines 36 and 37. Comments on the conflicts.  Asks the purpose for restricting information to law enforcement.

045

Schnabel

Answers clarification of database in lines 36 and 37 on page 2.

058

Sen. Metsger

Comments on possible issues with the bill.

060

Chair Morrisette

Comments on Oregon’s death to dignity law and states concern for doctors prescribing medication and with the medical marijuana bill.

078

Schnabel

Addresses the Chair’s concerns.

098

Sen. Metsger

States that he would like to hear legal analysis.

110

Chair Morrisette

States that he would like a study conducted to determine whether marijuana is an effective medical drug or not and if it could be dispensed in a pharmacy in a pill form.

112

Schnabel

Affirms Chair’s statement.

115

Chair Morrisette

Confirms that there is no recognition of marijuana for medical use.

117

Schnabel

Affirms.  Explains difference between the federal and state regulations.

127

Markuson

Explains how federal data is collected and how marijuana is not included.

130

Sen. Kruse

Asks what Schedule Marinol is under.

132

Schnabel

Answers Schedule II.

133

Sen. Kruse

Comments that there is a form of tetrahydrocannabinol  (THC) being prescribed.

140

Kathy Hahn

Chair, Oregon Pain Commission.  Testifies in opposition to SB 180.

173

Sen. Kruse

Comments on Hahn’s concerns. 

190

Chair Morrisette

Comments that there will be another public hearing for SB 180.  Closes public hearing on SB 180 and reopens public hearing on SB 756.

SB 756 – PUBLIC HEARING

217

Sen. Kate Brown

Senate District #21.  Submits and presents testimony in support of SB 756 (EXHIBIT I).

240

Rep. Carolyn Tomei

House District #41. Submits and presents testimony in support of SB 756 (EXHIBIT J).

305

Rep. Diane Rosenbaum

House District #42.  Submits and presents testimony in support of SB 756 (EXHIBIT K).

375

Cheryl Walker

Citizen, Grants Pass, Oregon.  Testifies in support of SB 756.

TAPE 25, B

003

Carol Robinson

Oregon Business Association.  Submits and presents testimony in support of SB 756 (EXHIBIT L).

050

Chair Morrisette

Reads and submits testimony written by Robert Castagna, Executive Director, Oregon Catholic Conference, who is in opposition of SB 756 (EXHIBIT M).

070

Rep. Debra Boone

House District #32.  Testifies in support of SB 756.

100

Laura Bridges

Board President, National Abortion and Reproduction Rights Action League (NARAL), Pro Choice Oregon.  Submits and presents testimony in support of SB 756 (EXHIBIT N).

112

Vicki Pedegana

Planned Parenthood.  Submits and presents written testimony in support of SB 756 (EXHIBIT O).

170

Michelle Goodin

Citizen, Springfield, Oregon.  Submits and presents testimony in support of SB 756 (EXHIBIT P).

The following material is submitted for the record without public testimony:

Leslye Epstein

President, National Council of Jewish Women, Portland Section.  Submits written testimony in support of SB 756 (EXHIBIT Q).

Paul Robinson

Reverend, United Church of Christ (ret.).  Submits written testimony in support of SB 756 (EXHIBIT R).

Jim Kelley

Owner, Rejuvenation.  Submits written testimony in support of SB 756 (EXHIBIT S).

Rosie Stephens

Action Committee, League of Women Voters of Oregon.  Submits written testimony in support of SB 756 (EXHIBIT T).

Alice Bartelt

Public Policy committee, American Association of University Women of Oregon.  Submits written testimony in support of SB 756 (EXHIBIT U).

Camille Roberts

NARAL Pro-Choice Oregon Marion and Polk County Chapter.  Submits written testimony in support of SB 756 (EXHIBIT V).

220

Chair Morrisette

Closes public hearing and opens a work session on SB 756.

SB 756 – WORK SESSION

233

Sen. Monnes Anderson

MOTION:  Moves SB 756 to the floor with a DO PASS recommendation.

237

VOTE:  3-2-0

AYE:               3 - Metsger, Monnes Anderson, Morrisette

NAY:               2 - Kruse, Starr C.

Chair Morrisette

The motion CARRIES.

SEN. BATES will lead discussion on the floor.

250

Sen. Kruse

Notes that he will be filing a Minority Report.

255

Chair Morrisette

Closes the work session on SB 756 and adjourns meeting at 4:58 p.m.